Basic Information
| LncRNA/CircRNA Name | DDX11-AS1 |
| Synonyms | NA |
| Region | GRCh38_12:31020763-31073847 |
| Ensemble | ENSG00000245614 |
| Refseq | NR_038927 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay |
| Sample | CRC cells (HCT116, SW480, LOVO, SW116) and FHC cells (control cells), CRC tissues and matched normal samples |
| Expression Pattern | up-regulated |
| Function Description | DDX11-AS1 as a new CRC-related lncRNA whose levels were distinctly up-regulated in CRC specimens and cell lines, partly induced by YY1. Clinical explorations suggested that increased expressions of DDX11- AS1 in CRC were positively associated with lymph nodes metastasis and TNM stage and had a distinct influence on the overall survival. Further multivariate assays indicated that DDX11-AS1 was an independent prognostic parameter implying a poorer clinical outcome for patients with CRC. Functional assays revealed that the knockdown of DDX11-AS1 suppressed the proliferation, migration, and invasion of CRC cells, and stimulate apoptosis. Mechanistic studies showed that the up-regulation of DDX11-AS1 competitively bound to miR-873 prevented CLDN7 from miRNAs-mediated degradations, thus facilitated the CRC progress. Further rescue assays were carried out to achieve confirmation. |
| Pubmed ID | 31298324 |
| Year | 2019 |
| Title | Long noncoding RNA DDX11-AS1 induced by YY1 accelerates colorectal cancer progression through targeting miR-873/CLDN7 axis |
External Links
| Links for DDX11-AS1 | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |